Injectable hydrogel helps bone marrow-derived mononuclear cells restore infarcted myocardium

Area of Science:

• Regenerative Medicine
• Biomaterials Science
• Cardiovascular Research

Background:

• Cell implantation shows potential for improving cardiac function post-myocardial infarction (MI).
• Limited cell engraftment and survival hinder the efficacy of current cell-based therapies for ischemic heart disease.
• Novel strategies are needed to enhance transplanted cell retention and function in the infarcted myocardium.

Purpose of the Study:

• To investigate the efficacy of hydrogel-encapsulated bone marrow-derived mononuclear cells (BMMNCs) for treating myocardial infarction.
• To assess whether hydrogel encapsulation improves BMMNC engraftment and survival in the infarcted cardiac tissue.
• To evaluate the impact of this approach on restoring cardiac function and cardiac remodeling.

Main Methods:

• Myocardial infarction (MI) was induced in rabbits via coronary artery ligation.
• Bone marrow-derived mononuclear cells (BMMNCs) were encapsulated in a Dex-PCL-HEMA/PNIPAAm hydrogel.
• BMMNCs, either in medium or encapsulated in hydrogel, were injected into the left ventricle's infarcted area.

Main Results:

• Hydrogel encapsulation significantly increased BMMNC engraftment at 48 hours post-injection.
• Echocardiography at 30 days revealed preserved left ventricular ejection fraction and attenuated dilatation in the hydrogel-BMMNC group.
• Histological analysis demonstrated enhanced neovascularization and reduced scar expansion with hydrogel-encapsulated BMMNCs.

Conclusions:

• Injection of hydrogel-encapsulated BMMNCs effectively enhances cell engraftment and improves cardiac function after MI.
• This technique represents a promising therapeutic approach for the regeneration of infarcted myocardium.
• Hydrogel-based cell delivery systems offer a viable strategy to overcome limitations in current cell transplantation therapies.